hero image

Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015

December 23, 2014 Investor Relations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2014 financial results on Wednesday, January 28, 2015, before the financial markets open.

Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:30 am ET. To access the live webcast, please go to the investor relations section of Biogen Idec’s website at www.biogenidec.com. Following the live webcast, an archived version of the call will be available at the same URL, for one month.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

 

Biogen Idec
Karen Jewell, 781-464-2442
Investor Relations

 

 

thumb
October 6, 2021
Biogen to Report Third Quarter 2021 Financial Results October 20, 2021

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report third quarter 2021 financial results Wednesday, October 20, 2021, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

thumb
October 4, 2021
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress

Improvement achieved in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical program Sage to host conference call on October 4, 2021 at 8:00am ET